55 results about "Membrane antigen" patented technology

The present disclosure relates to the synthesis of prostate-specific membrane antigen (PSMA) ligands useful in the treatment of diseases such as cancer. In particular, the present disclosure relates to methods for synthesizing PSMA ligands having a glutamic acid-urea-lysine (GUL) moiety and a chelator that may include a radiometal.

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

Disclosed herein are isolated polypeptide and polypeptide complex compositions that comprise a prostate-specific membrane antigen (PSMA) binding domain that is linked to a peptide that impairs binding of the PSMA binding domain to PSMA.

This invention provides a combination for use in treating cancers that express prostate-specific membrane antigen (PSMA). [Solution] A combination comprising a PD-1 inhibitor, a CTLA-4 inhibitor, and a radiolabeled compound of formula Ia for use in treating PSMA-expressing cancer in the subject. JPEG2026049728000042.jpg45132 The aforementioned combination comprises one or more further anticancer agents, wherein the further anticancer agents are selected from octreotide, lanreotide, vapreotide, pasireotide, satreotide, everolimus, temozolomide, telotristat, sunitinib, sulfatinib, ribociclib, entinostat, and pazopanib.

The present invention discloses a complex comprising (a) a compound, which is CA007 *, CA008 *, or CA009 *, or a pharmaceutically acceptable salt thereof, and (b) a radionuclide, which is selected from the group consisting of 203Pb and 212Pb. Also disclosed is the use of said complexes in the manufacture of a medicament for the treatment of cancers expressing prostate specific membrane antigen (PSMA). (CA007 *) (CA008 *) (CA009 *)

Imaging and radiotherapeutic agents targeting fibroblast-activation protein-α (FAP-α) and / or prostate-specific membrane antigen (PSMA) and their use in imaging and treating FAP-α and / or PSMA-related diseases and disorders are disclosed.

A treatment for patients having cancer expressing Prostate Cancer Specific Membrane Antigen (PSMA) is disclosed. Said treatment involves the use of an 225Ac-radioconjugate, in particular 225Ac-PSMA-I&T. A dosage regimen that entails more frequent administration of the 225Ac-radioconjugate at lower dose level may be employed. This involves the use of a dosage of 50-75 kBq / kg of body weight on a dosing schedule of every 4-6 weeks. A flat dosing may also be employed where the dose does not depend on the body weight of the subject. Such dosing improve the benefit / risk profile with fewer adverse events and less discontinuations, dosing interruptions and reductions in dose. Of particular importance is a reduction in salivary gland toxicity and xerostomia.

A prostate-specific membrane antigen (PSMA)-targeting ligand compound and a chelate thereof and use thereof are provided. The PSMA-targeting ligand compound has a structure as shown in formula I, where R1, R2 and R4 are each independently selected from the group consisting of H and optionally substituted linear or branched C1-C5 alkyl; R3 is selected from the group consisting of optionally substituted aryl and optionally substituted heteroaryl; X is a sulfur atom or an oxygen atom; Y is selected from the group consisting of a chemical bond and —NH—(CH2)m-, where m is an integer selected from 0-18; and Z is a radioactive metal ion chelating group.

A method for imaging inflammation associated with inflammatory bowel disease (IBD) has been disclosed, which involves administering an imaging agent targeting prostate-specific membrane antigen (PSMA) to a subject and acquiring images.

Provided herein are, inter alia, methods of treating prostate cancer in a subject by administering to the subject a combination comprising i) a chimeric polypeptide targeting PSMA and CD3, and ii) an androgen receptor antagonist.

The present application relates to the technical field of medicine, in particular to a functional nanomaterial based on choline phosphate-cell membrane interaction and application thereof.The present application modifies manganese mineralized black phosphorus nanomaterial by bio-inspired polymer pGluCP adsorption, which retains the excellent biocompatibility and photothermal performance of BP, and at the same time, pGluCP enhances the 'chassis' effect of the material, captures tumor-related antigens, and can simultaneously capture water-soluble antigens and water-insoluble membrane antigens and form pathogen-like micro-nanoparticles, which is helpful for antigen delivery and APC presentation, and provides a feasible tool for capturing non-water-soluble membrane antigens, which is a major challenge.MnBP and pGluCP synergistically act, and can realize the personalized conversion of autologous tumors to vaccine production and delivery.

Disclosed herein are modified HIV envelope immunogens, engineered nanoparticle vaccines comprising modified HIV envelope immunogens and methods of use thereof for HIV vaccines.

The present invention relates to a method for the detection and diagnosis of cancer associated with overexpression of prostate specific membrane antigen (PSMA) by administering a 64Cu-labeled sarcophagine compound Sar-bis PSMA in a dose of from about 100 MBq to about 300 MBq, and PET imaging of a patient, and a method for the detection and diagnosis of cancer associated with overexpression of prostate specific membrane antigen (PSMA) by administering a 64Cu-labeled sarcophagine compound Sar-bis PSMA in a dose of from about 100 MBq to about 300 MBq. The method allows for higher resolution images even at cancer sites with lower PSMA density, such as secondary lesions.

To provide prostate-specific membrane antigen (PSMA) ligands, and in particular, alternative multimodal PSMA ligands suitable for use as diagnostics and / or therapeutics.SOLUTION: The present disclosure provides PSMA ligands having: a glutamate-urea-lysine (GUL) moiety; a radioisotope; and a chelating agent that can comprise a radiometal.SELECTED DRAWING: None

The present disclosure relates to antigen-binding domains which bind the antigen prostate-specific membrane antigen (PSMA) and to chimeric antigen receptors (CARs) which comprise such antigen binding domains.

The present invention relates to a polyplex comprising a linear conjugate of LPEI and PEG. The LPEI and PEG fragments of the linear conjugate are preferably linked by a [3+2] cycloaddition between azide and alkene or alkyne to generate 1,2,3 triazole or 4,5-dihydro-1H-[1,2,3]triazole. The linear conjugate is further conjugated to a targeting fragment that can bind to prostate-specific membrane antigen (PSMA) to enable selective interaction with specific cell types. The conjugate can form a polyplex with a therapeutic agent, such as a nucleic acid, to deliver the therapeutic agent to cells.

PSMA targeted metal chelate nanodrugs, methods of making these nanodrugs and methods of using them for radiodiagnosis and radiotherapy are provided.

Conjugates of the formula T-L-A wherein T is a ligand targeting prostate specific membrane antigen (PSMA), L is a linker, and A is a radiosensitizer; a pharmaceutical composition comprising the conjugate and a pharmaceutically acceptable carrier; and methods of treating prostate cancer or metastases thereof in a patient using radiotherapy. A conjugate of formula T-L-A can be administered prior to or after administration of a conjugate of formula T-L-X, wherein X is or comprises a radiotherapy or (radiation) imaging agent. Conjugates of formula T-L-(X) A, pharmaceutical compositions comprising the same, and methods of use are also disclosed.

The invention discloses a tumor holoantigen nano vaccine as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The nano vaccine comprises a composite liposome, a nucleic acid TLR agonist adjuvant, a tumor cell membrane antigen and a tumor cell soluble antigen. The membrane antigen is embedded into the lipid bilayer, and the soluble antigen and the adjuvant are wrapped in the inner cavity of the lipid to form the nanoparticles with accurate structures. The preparation method comprises the following steps: splitting a tumor cell separation membrane antigen and a soluble antigen; mixing the membrane antigen and lipid to form a lipid phase, and mixing the soluble antigen and an adjuvant to form a water phase; finally, the two phases are self-assembled into the nano vaccine through a micro-fluidic chip. The two antigens are synergistically combined at the nanoscale, the problems that a single antigen is weak in immunogenicity and incomplete in coverage are solved, the synergic anti-tumor effect far better than that of a single antigen vaccine is shown in an animal model, the preparation process is universal and controllable, and an efficient platform is provided for individualized tumor immunotherapy.

This invention relates to the field of optical imaging. More specifically, it relates to fluorescent probes capable of effectively targeting prostate-specific membrane antigen (PSMA) and comprising heptamethrin dye having near-infrared (NIR) emission. The invention also relates to methods for preparing these compounds, pharmaceutical compositions and kits for introducing these compounds, and methods for using them as optical diagnostic agents in the imaging or treatment of diseases, particularly prostate cancer.

Disclosed herein are isolated polypeptide and polypeptide complexes that comprise a first antigen recognizing molecule that binds to an effector cell antigen and a second antigen recognizing molecule that binds to prostate-specific membrane antigen (PSMA), wherein the second antigen recognizing molecule is linked to a peptide that impairs binding of the second antigen recognizing molecule to PSMA.

Immunogenic and vaccine compositions containing a Neisseria gonorrhoeae lipooligosaccharide (LOS), or a fragment thereof, are provided. The LOS may be conjugated to a carrier such as a carrier protein, virus-like particle (VLP), liposome, inorganic gold particle, dendrimer, outer membrane vesicle (OMV), generalized modules for membrane antigens (GMMA), and protein nanocages. Methods of protecting or treating a subject from Neisseria gonorrhoeae infection and methods of manufacturing the compositions are also provided.

The invention discloses an mRNA vaccine based on a tumor-retina antigen and application thereof, and relates to the field of breast cancer treatment. The method comprises the following steps: firstly, analyzing transcriptome data and immunohistochemical staining results of a human body, and screening out PDE6G protein which is highly expressed only in normal retina tissues and breast cancer cells of the human body; then, the protein is used as an antigen, a corresponding mRNA vaccine is designed and prepared, and the function and the biological safety of the vaccine are verified on the aspects of cells, tissues and organs. In conclusion, a new target spot and a new mRNA vaccine are provided for treatment of the breast cancer, a theoretical basis is laid for diversified treatment of the breast cancer, and meanwhile, the target spot and the mRNA vaccine have huge application prospects.

This application relates to compounds of Formula I. R1a, R1b and R1c is —CO2H, —SO2H, —SO3H, —SO4H, —PO2H, —PO3H or —PO4H. R2 is a linker, e.g. butylene. R3 is a linkage, e.g. —O—, —S—, —S(O)—, S(O)2—, —NHC(O)—, —C(O)NH—, or 1,2,3-triazole. R4 is —(CH2)0-3CH(R7)(CH2)0-3— wherein R7 is —(CH2)5CH3 or certain aromatic fused-ring systems. R5 and R6 are hydrogen or methyl. Each Xaa1 (if present) is an amino acid. RX is a radiolabeling group, e.g.: a radiometal chelator optionally bound by a radiometal; an aryl substituted with a radioisotope; a prosthetic group containing a trifluoroborate; or a prosthetic group containing a silicon-fluorine-acceptor moiety. The compounds may be useful for imaging prostate-specific membrane antigen (PSMA)-expressing tissues or for treating PSMA-expressing diseases (e.g. cancer).

Provided herein are compounds of Formula (I), pharmaceutical compositions comprising the compounds, and methods of using the compounds or pharmaceutical compositions to diagnose or treat a disease or condition, such as a disease or condition characterized by overexpression of prostate specific membrane antigen (PSMA). (I).

The present disclosure relates to a method for treating prostate-specific membrane antigen (PSMA)-positive advanced metastatic castration-resistant prostate cancer (mCRPC) by administering a therapeutically effective amount of a PSMA-conjugated radioligand therapy (RLT) agent, preferably [177Lu]Lu-PSMA-617 (lutetium (177Lu) bipibotide tetraxetane), to taxane-naive patients who have progressed after receiving a second-generation ARPI.

A ligand-SiFA conjugate compound represented by formula (1) wherein: RL is a ligand moiety which is capable of binding to prostate-specific membrane antigen (PSMA); RSiFA is a silicon-fluoride acceptor (SiFA) moiety which can be labeled with 18F or which is labeled with 18F; L is a linking moiety; RH is a hydrophilic moiety which comprises (i) a linear or branched sequence of 2 to 10 hydrophilic amino acid units AH, each of which is independently derived from a natural or non-natural amino acid carrying a hydrophilic side chain, and optionally one amino acid unit AN derived from a natural or non-natural amino acid which is devoid of a hydrophilic side chain, wherein the hydrophilic amino acid units and, if present, the unit AN, are bound to each other via a direct covalent bond or via a coupling unit; and which optionally further comprises (ii) one or more hydrophilic residues RT, each of which may be bound to an amino group, a carboxylic acid group, or to a hydrophilic side chain of an amino acid unit; or a pharmaceutically acceptable salt thereof.

Described herein are combination therapies featuring a Prostate- Specific Membrane Antigen (PSMA)-targeting radiopharmaceutical, in particular [177Lu]Lu-PSMA-617, and an Androgen Receptor (AR) -degrading agent, in particular luxdegalutamide, and their use in treating cancers, such as, e.g., PSMA-expressing cancers.

The present disclosure relates to compounds targeting prostate specific membrane antigen (PSMA) conjugated to near infrared (NIR) dyes, and methods of their therapeutic and diagnostic use. More particularly, the present disclosure provides compounds and methods for the diagnosis and treatment of diseases associated with cells and / or vasculature expressing prostate specific membrane antigen (PSMA), such as prostate cancer and related diseases. The disclosure also describes methods and compositions for making and using the compounds, methods including the compounds, and kits including the compounds.